Cyteir Therapeutics, Inc. Stock Price, News & Analysis

Cyteir Therapeutics (Nasdaq: CYT) reported significant advancements in its lead program, CYT-0851, with Phase 2 monotherapy expansion cohorts underway. The company achieved a positive interim analysis demonstrating disease control in 20 of 46 patients. They finished 2021 with approximately $190 million in cash, projected to fund operations into 2024. R&D expenses rose to $31 million for the year, alongside a net loss of $42.1 million. A conference call on March 16, 2022, will provide further insights into their financial results and operational progress.

Cyteir Therapeutics, Inc. (NASDAQ: CYT) will host a conference call on March 16, 2022, at 4:30 p.m. ET, to discuss its fourth quarter and full year 2022 financial and operational results. Interested parties can access the live audio webcast on the company's website and the archived version will be available for 30 days. Cyteir is focused on developing next-generation synthetically lethal therapies for cancer, with its lead compound, CYT-0851, targeting DNA repair mechanisms in cancer cells.

Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced the appointment of Stephen Sands to its Board of Directors effective February 22, 2022. Sands, who has over 25 years of experience in investment banking and healthcare, will also serve on the Audit Committee. The board size has increased to ten members. Sands aims to leverage his expertise to help advance Cyteir's corporate strategy and its lead compound, CYT-0851, designed for cancer treatment.

Cyteir Therapeutics (NASDAQ: CYT) announced the first patient dosed in a Phase 2 expansion cohort study of CYT-0851, targeting hematologic malignancies and solid tumors. This study aims to evaluate anti-tumor activity across six cancer types and confirm the safety of the drug, which is designed to inhibit RAD51-mediated DNA repair. Management expressed optimism about advancing CYT-0851 into a potential registrational trial by early next year, contingent on the study results.

Cyteir Therapeutics has appointed John F. Thero to its board of directors, expanding the board from eight to nine members. Thero, who brings over 30 years of experience in financial and operations roles, will chair the audit committee. He is recognized for leading Amarin through critical phases, including the launch of VASCEPA, and has received accolades such as Ernst & Young's Entrepreneur of the Year for Life Sciences. Thero expressed enthusiasm about contributing to Cyteir's growth, targeting advancements in their candidate CYT-0851 for oncology patients.

Cyteir Therapeutics (NASDAQ: CYT) announced the first patient has been dosed in a Phase 1 trial for its investigational drug CYT-0851. This trial evaluates CYT-0851 in combination with three chemotherapy regimens for hematologic malignancies and solid tumors. The drug aims to inhibit double-strand DNA repair, potentially expanding treatment options across various cancers. Initial safety data is anticipated by year-end, with further development expected if successful.

Cyteir Therapeutics, Inc. (Nasdaq: CYT) announced that its President and CEO, Markus Renschler, MD, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM ET. The virtual event allows investors to access a live webcast on the Cyteir website, with a replay available for 30 days after the presentation. Cyteir is a clinical-stage oncology company focused on developing next-generation synthetically lethal therapies for cancer, including its lead compound, CYT-0851, aimed at inhibiting RAD51-mediated homologous recombination.

Cyteir Therapeutics (NASDAQ:CYT) announced the appointment of Dr. Jeffrey S. Humphrey, MD, as a new member of its Board of Directors. Dr. Humphrey, the Chief Medical Officer of Magenta Therapeutics, brings extensive experience in clinical research and drug development, having led multiple drug approvals. His expertise aligns with Cyteir's mission to develop innovative cancer therapies, particularly the investigational drug CYT-0851. Additionally, Karen Hong, PhD, has resigned from the board, allowing for leadership transition aimed at advancing Cyteir's clinical pipeline.

Cyteir Therapeutics reported significant advancements in its oncology pipeline, particularly for CYT-0851. The company has identified a Phase 2 dose of 400 mg daily following a successful dose-escalation study, aiming to initiate Phase 2 expansion studies in early 2022. Financially, Cyteir ended Q3 2021 with approximately $200 million in cash. R&D expenses rose to $8.2 million, reflecting increased clinical activity, while G&A expenses surged to $3.5 million. The net loss for the quarter was $11.7 million, compared to $5.0 million in the prior year.